Cover Image
市場調查報告書

Gene Signal International SA.:產品平台分析

Gene Signal International SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 192601
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
Gene Signal International SA.:產品平台分析 Gene Signal International SA - Product Pipeline Review - 2015
出版日期: 2015年05月13日 內容資訊: 英文 29 Pages
簡介

Gene Signal International SA.是研究開發血管新生相關的疾病治療用oligo核苷酸、蛋白質及單株抗體的生物科技企業。

本報告提供Gene Signal International SA.的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Gene Signal International SA的基本資料

Gene Signal International SA概要

  • 主要資訊
  • 企業資料

Gene Signal International SA:R&D概要

  • 主要的治療範圍

Gene Signal International SA:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Gene Signal International SA:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Gene Signal International SA:藥物簡介

  • aganirsen
  • GS-156
  • GS-168
  • GS-497-c
  • GS-156 MAb

Gene Signal International SA:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Gene Signal International SA:最近的開發平台趨勢

Gene Signal International SA:暫停中的計劃

Gene Signal International SA:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07073CDB

Summary

Global Markets Direct's, 'Gene Signal International SA - Product Pipeline Review - 2015', provides an overview of the Gene Signal International SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Gene Signal International SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Gene Signal International SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Gene Signal International SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Gene Signal International SA's pipeline products

Reasons to buy

  • Evaluate Gene Signal International SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Gene Signal International SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Gene Signal International SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Gene Signal International SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Gene Signal International SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Gene Signal International SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Gene Signal International SA Snapshot
    • Gene Signal International SA Overview
    • Key Information
    • Key Facts
  • Gene Signal International SA - Research and Development Overview
    • Key Therapeutic Areas
  • Gene Signal International SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Gene Signal International SA - Pipeline Products Glance
    • Gene Signal International SA - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Gene Signal International SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Gene Signal International SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Gene Signal International SA - Drug Profiles
    • aganirsen
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GS-156
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GS-168
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GS-497c
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GS-156 mAB
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Gene Signal International SA - Pipeline Analysis
    • Gene Signal International SA - Pipeline Products by Target
    • Gene Signal International SA - Pipeline Products by Route of Administration
    • Gene Signal International SA - Pipeline Products by Molecule Type
    • Gene Signal International SA - Pipeline Products by Mechanism of Action
  • Gene Signal International SA - Recent Pipeline Updates
  • Gene Signal International SA - Dormant Projects
  • Gene Signal International SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Gene Signal International SA, Key Information
  • Gene Signal International SA, Key Facts
  • Gene Signal International SA - Pipeline by Indication, 2015
  • Gene Signal International SA - Pipeline by Stage of Development, 2015
  • Gene Signal International SA - Monotherapy Products in Pipeline, 2015
  • Gene Signal International SA - Phase III, 2015
  • Gene Signal International SA - Phase II, 2015
  • Gene Signal International SA - Phase I, 2015
  • Gene Signal International SA - Preclinical, 2015
  • Gene Signal International SA - Discovery, 2015
  • Gene Signal International SA - Pipeline by Target, 2015
  • Gene Signal International SA - Pipeline by Route of Administration, 2015
  • Gene Signal International SA - Pipeline by Molecule Type, 2015
  • Gene Signal International SA - Pipeline Products by Mechanism of Action, 2015
  • Gene Signal International SA - Recent Pipeline Updates, 2015
  • Gene Signal International SA - Dormant Developmental Projects,2015
  • Gene Signal International SA, Subsidiaries

List of Figures

  • Gene Signal International SA - Pipeline by Top 10 Indication, 2015
  • Gene Signal International SA - Pipeline by Stage of Development, 2015
  • Gene Signal International SA - Monotherapy Products in Pipeline, 2015
  • Gene Signal International SA - Pipeline by Top 10 Target, 2015
  • Gene Signal International SA - Pipeline by Top 10 Route of Administration, 2015
  • Gene Signal International SA - Pipeline by Top 10 Molecule Type, 2015
  • Gene Signal International SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top